Protara Therapeutics (NASDAQ:TARA) is a clinical-stage biopharmaceutical company focused on developing novel molecular therapies for fibrotic and inflammatory diseases of the gastrointestinal (GI) tract. Leveraging its proprietary LAMBDA albumin-binding platform, Protara is advancing targeted treatments designed to enhance drug half-life and tissue penetration. The company’s lead candidate, PTI-801, is a long-acting anti-IL-13 monoclonal antibody currently in Phase 2 clinical trials for eosinophilic esophagitis, an underserved inflammatory disorder characterized by eosinophil-driven tissue damage in the esophagus.
In addition to PTI-801, Protara’s pipeline includes preclinical programs aimed at addressing fibrosis and inflammation in the GI tract, with particular emphasis on conditions such as eosinophilic gastritis, eosinophilic colitis, and other eosinophil-mediated diseases. The LAMBDA platform allows for the conjugation of engineered albumin to diverse therapeutic modalities, including antibodies and small proteins, offering the potential for optimized pharmacokinetic profiles and improved patient dosing schedules.
Founded in 2019 and headquartered in Irvine, California, Protara draws on a team of scientists and drug development professionals with extensive experience in immunology, gastroenterology, and biologics manufacturing. The company collaborates with academic institutions, contract research organizations, and clinical investigators across North America and Europe to design and execute its clinical development programs, ensuring rigorous evaluation of safety and efficacy.
Protara is led by a management team with proven track records in biotechnology and pharmaceutical development, supported by a board of directors possessing deep expertise in commercial strategy and regulatory affairs. With a strategic focus on advancing its lead and follow-on candidates through clinical milestones, Protara aims to address significant unmet medical needs in GI fibrosis and inflammation, ultimately seeking to deliver transformative therapies to patients worldwide.
